Table 2.
Individual description of cases.
| Patient/sex | Age/age at onset (years) | GGE syndrome | Persistent seizuresa | Seizure frequency before LCMa | ASD regime (mg/24 h) | Clinical responseb | Details |
|---|---|---|---|---|---|---|---|
| 1/F | 43/20 | JME | GTCS | 1/6 m | LCM 200 LEV 1000 |
Yes | 2 y SzF on LCM up to date |
| 2/M | 39/6 | CAE persisting into adulthood | ABS and GTCS | 2 GTCS/6 m Weekly ABS |
LCM 300 VPA 1200 LEV 1000 |
Yes | After 3,5 y SzF on LCM, he suffered 2 GTCS (one provoked) in the last year |
| 3/F | 53/5 | CAE persisting into adulthood | GTCS | 3/6 m | LCM 400 LEV 3000 VPA 1000 |
Yes | 6 y SzF on LCM up to date |
| 4/M | 48/14 | GTCS alone | GTCS | 2/6 m | LCM 200 VPA 1000 |
Yes | ABS status on CBZ in the past 5 y SzF on LCM up to date |
| 5/F | 50/12 | GTCS alone | GTCS | 3/6 m | LCM 200 LEV 2000 |
Yes | 3,5 y SzF on LCM up to date |
| 6/M | 63/10 | JME | ABS, myoclonic and GTCS | 6 GTCS/6 m NQ for myoclonic and ABS |
LCM 300 VPA 1300 |
Yes | 3 y SzF on LCM up to date |
| 7/F | 33/24 | JAE | ABS and GTCS | 2 GTCS/6 m NQ for ABS (“sporadic”) |
LCM 400 VPA 1600 |
Yes | Subjective ABS increase 1,5 y GTCS-SzF on LCM up to date |
| 8/M | 35/17 | GTCS alone | GTCS | 2/6 m | LCM 400 VPA1500 |
No | Similar. SzF after adding VPA to LCM (attributed to VPA) |
| 9/M | 58/11 | JAE | GTCS | 2/6 m | LCM 150 LTG 400 |
No | Myoclonic and absence status |
GTCS generalized tonic–clonic seizure; ABS absences; NQ not able to quantify; y years; m months; SzF seizure free; LEV levetiracetam; VPA valproate; LTG lamotrigine.
a
In the 6 months prior to LCM treatment onset.
b
50% or greater reduction in GTCS frequency.